Fulgent Genetics (NASDAQ:FLGT - Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.330-0.330 for the period, compared to the consensus estimate of -0.390. The company issued revenue guidance of $280.0 million-$280.0 million, compared to the consensus revenue estimate of $282.2 million. Fulgent Genetics also updated its FY24 guidance to $0.33 EPS.
Fulgent Genetics Price Performance
Shares of FLGT stock traded down $2.59 on Friday, hitting $19.43. 538,971 shares of the stock traded hands, compared to its average volume of 179,608. The company has a market capitalization of $588.73 million, a PE ratio of -3.55 and a beta of 1.51. The company's fifty day moving average is $21.01 and its 200 day moving average is $21.43. Fulgent Genetics has a 1-year low of $18.76 and a 1-year high of $30.68.
Insider Transactions at Fulgent Genetics
In related news, CEO Ming Hsieh sold 2,313 shares of the business's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the sale, the chief executive officer now owns 707,275 shares of the company's stock, valued at $16,147,088.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have sold 4,324 shares of company stock worth $98,717. 32.66% of the stock is currently owned by insiders.
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Further Reading
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
